NCT04666675View on ClinicalTrials.gov

A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 24, 2020

Primary Completion Date

March 23, 2021

Study Completion Date

March 23, 2021

Conditions
Atopic Dermatitis (AD)
Interventions
DRUG

Upadacitinib

Oral; Tablet

DRUG

Placebo for Upadacitinib

Oral; Tablet

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY